Breakdown of funding for the saRNA SARS-CoV-2 lipid nanoparticle vaccine

Sarai Keestra made this Freedom of Information request to Imperial College London

Automatic anti-spam measures are in place for this older request. Please let us know if a further response is expected or if you are having trouble responding.

The request was successful.

Dear Imperial College London,

Under the Freedom of Information Act 2000, please provide me with all of the following:

1. A breakdown of all funding (including all financial support, grants, donations, etc.) that has been received by Imperial College London relating to saRNA vaccine platform, from the earliest date for which information is available to the present day. Please include:
the grant number (if available) and date.
1a. Please break funding down into 1) funding from public (governmental) bodies, 2) private entities, and 3) philanthropies/charitable bodies.
1b. Please provide the full name of the funding body
1c. Please specify amounts in GBP.

Relevant keywords for such funding may include: saRNA, Self-amplifying RNA vaccine, lipid nanoparticle (LPN), lipid nanoparticle (LPN) vaccine, saRNA vaccine platform, alphavirus, alphaviral replicase, HIV vaccine

2. What is the amount of grant funding from government entities (such as the Medical Research Council, or other research funders) that Imperial College London has received, since 1 January 2020, for projects relating to the development of the RNA SARS-CoV-2 lipid nanoparticle vaccine specifically? Please include the grant number (if available) and date.
2a. Please break funding down into 1) funding from public (governmental) bodies, 2) private entities, and 3) philanthropies/charitable bodies.
2b. Please provide the full name of the funding body
2c. Please specify amounts in GBP.

Relevant keywords for such funding may include: RNA SARS-CoV-2 lipid nanoparticle vaccine, COVID-19 vaccine, saRNA vaccine platform, SARS-CoV-2 spike protein, saRNA, Self-amplifying RNA vaccine, lipid nanoparticle (LPN), lipid nanoparticle (LPN) vaccine, saRNA vaccine platform, alphavirus, alphaviral replicase, COVAC1, COVID-19 vaccine trial

END OF FOI

Format: please provide the reply to our request in the form of an Excel sheet where possible.

Thank you very much for your effort.

Yours faithfully,

Sarai Keestra

IMPFOI, Imperial College London

Dear Ms Keestra,

 

Thank you for your email. We are writing to you for further clarity on the
specific research work that your request relates to.

 

There is extensive information on our website about Imperial College's
research activity, including the [1]COVID-19 vaccine.
[2]https://www.imperial.ac.uk/covid-19-vacc...

 

If you are able to point us to the specific research activity to which
your request relates, we would then be able to identify who to approach
for the information you are seeking.

 

Yours,

 

Freedom of Information Team

Imperial College London 

 

show quoted sections

Dear IMPFOI,

Thank you for your response. As specified in my original request, I am requesting a breakdown of all funding into the saRNA vaccine platform (question 1) and the COVID-19 vaccine developed using this platform (question 2) from the earliest date that records are available until now. This relates but may not be limited to the work of Prof. Shattock and his research group. Please use the keywords I have provided in my request to identify relevant funding sources. Please disclose ALL funding Imperial has received for developing these health technologies.

Yours sincerely,

Sarai Keestra

IMPFOI, Imperial College London

Dear Ms Keestra,

This is to acknowledge receipt of your request below, made under the Freedom of Information Act. The College will respond to your request by 1 December.

Yours,

Freedom of Information Team
Imperial College London 

show quoted sections

IMPFOI, Imperial College London

1 Attachment

Dear Ms Keestra,

Thank you for your Freedom of Information Act request, which was as
follows:

1. A breakdown of all funding (including all financial support, grants,
donations, etc.) that has been received by Imperial College London
relating to saRNA vaccine platform, from the earliest date for which
information is available to the present day. Please include:

the grant number (if available) and date.

1a. Please break funding down into 1) funding from public (governmental)
bodies, 2) private entities, and 3) philanthropies/charitable bodies.

1b. Please provide the full name of the funding body 1c. Please specify
amounts in GBP.

 

2. What is the amount of grant funding from government entities (such as
the Medical Research Council, or other research funders) that Imperial
College London has received, since 1 January 2020, for projects relating
to the development of the RNA SARS-CoV-2 lipid nanoparticle vaccine
specifically? Please include the grant number (if available) and date.

2a. Please break funding down into 1) funding from public (governmental)
bodies, 2) private entities, and 3) philanthropies/charitable bodies.

2b. Please provide the full name of the funding body 2c. Please specify
amounts in GBP.

 

The attached spreadsheet shows details of all research awards and
donations received that we believe fall within the scope of your request
based on a search of either the award title, your suggested keywords, the
funders and Professor Shattock being an investigator. Please note that due
to the keywords you have used, some of the research awards are not
primarily related to saRNA Sars-Cov-2 work, such as the ‘Injectable
Crosslinked Long-Acting Formulations’ Gates Foundation award. 

If you are unhappy with the way that we have handled your request, you can
ask us to conduct a review. Please make your representation in writing
within 40 days of the date you received this response. If you remain
dissatisfied with how Imperial College has handled your request, you may
then approach the [1]Information Commissioner’s Office.   

 

Yours,

 

Freedom of Information Team

[2]Imperial College London 

 

show quoted sections